RBM22P4

Across TCGA pan-cancer cohorts, RBM22P4 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RBM22P4’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where RBM22P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RBM22P4 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

UCEC, THCA, and LIHC are the cancer types where RBM22P4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBM22P4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	IV	+0.235	.034	2	view →
THCA	Female	All	−0.019	.020	2	view →
LIHC	All	All	+0.011	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RBM22P4–UCEC

Open the UCEC breakdown →